inflammatory bowel disease (IBD)
Nov 29, 2018
Prometic bags $50M; Vedanta receives $12M; Humira biosimilar deal
Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This gives Prometic a way to escape its current financial pressures. Canada-based Prometic was asked by the FDA to make and validate process changes for Ryplazim, a c...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
